Powder: -20°C for 3 years | In solvent: -80°C for 1 year
VS-5584 (SB2343) 是pan-PI3K/mTOR 激酶抑制剂。它能够阻断mTORC2和mTORC1。它能够抑制 PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ 和 mTOR,IC50分别为 16 nM, 68 nM, 42 nM, 25 nM 和 37 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 281 | 现货 | ||
2 mg | ¥ 413 | 现货 | ||
5 mg | ¥ 747 | 现货 | ||
10 mg | ¥ 970 | 现货 | ||
25 mg | ¥ 1,670 | 现货 | ||
50 mg | ¥ 2,490 | 现货 | ||
100 mg | ¥ 3,730 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 822 | 现货 |
产品描述 | VS-5584 (SB2343) is a pan-PI3K/mTOR kinase inhibitor. |
靶点活性 | mTOR:3.4 nM, PI3Kγ:3.0 nM, PI3Kα:2.6 nM, PI3Kβ:21 nM, PI3Kδ:2.7 nM |
体外活性 | VS-5584 is an ATP-competitive inhibitor which selectively inhibits PI3K/mTOR signaling with equivalent low nanomolar potency against all human Class I PI3K isoforms and mTOR kinase. VS-5584 is approximately 10-fold selective for cancer stem cells with an EC50 of 15 nM in HMLE breast cancer cells. VS-5584 preferentially decreases CD44Hi/CD24Lo cells in an HMLER immortalized mammary cancer cell line. In SUM159 cells, VS-5584 effectively eliminates the cancer stem cell side population. [1] A large human cancer cell line panel screen (436 lines) reveals broad antiproliferative sensitivity and that cells harboring mutations in PI3KCA are generally more sensitive toward VS-5584 treatment. In the FLT3-ITD harboring MV4-11 cells, VS-5584 blocks pAkt (S473) and pAkt (T308) with IC50 of 12 and 13 nM, respectively. The IC50 of VS-5584 for pS6 (S240/244), pAkt (S473), and pAkt (T308) are 20, 23, and 15 nM, respectively. [2] |
体内活性 | In mice bearing triple negative breast cancer tumors, oral dosing of VS-5584 decreases tumor cancer stem cells and induces tumor regression in taxane-resistant models. [1] In a PTENnull human prostate PC3 xenograft model, treatment with VS-5584 leads to significant tumor growth inhibition (TGI) of 79% and 113% for 11 and 25 mg/kg, respectively. In a FLT3-ITD AML xenograft model, VS-5584 treatment induces dose-dependent inhibition of tumor growth (28% for 3.7 mg/kg and 76% for 11 mg/kg). [2] |
激酶实验 | In vitro mTOR kinase assays : The reaction mixture consisted of the following components in 10 μL assay buffer (50 mM Hepes pH 7.5, 10 mM MgCl 2, 3 mM MnCl 2, 1 mM EGTA, 2 mM DTT, 0.01%Tween-20): 0.10 μg/mL of in-house generated mTOR enzyme, 0.05 μM ULight-eIF4E-binding protein 1 (Thr37/46) peptide and 10 μM ATP. The mixture is incubated for 60 min at room temperature. 10 μL of Detection mixture consisted of 16 mM EDTA, 0.004 mM Eu-W1024-labeled Anti-Phospho-eIF4E-binding protein 1-(Thr37/46) antibody and 1X LANCE? Detection Buffer is then added and incubated for 60 min. |
细胞实验 | CellTiter-Glo assay(Only for Reference) |
别名 | SB2343, VS 5584, VS5584 |
分子量 | 354.41 |
分子式 | C17H22N8O |
CAS No. | 1246560-33-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 3 mg/mL (8.46 mM)
DMSO: 66 mg/mL (186.2 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 2.8216 mL | 14.108 mL | 28.2159 mL | 70.5398 mL |
5 mM | 0.5643 mL | 2.8216 mL | 5.6432 mL | 14.108 mL | |
DMSO | 10 mM | 0.2822 mL | 1.4108 mL | 2.8216 mL | 7.054 mL |
20 mM | 0.1411 mL | 0.7054 mL | 1.4108 mL | 3.527 mL | |
50 mM | 0.0564 mL | 0.2822 mL | 0.5643 mL | 1.4108 mL | |
100 mM | 0.0282 mL | 0.1411 mL | 0.2822 mL | 0.7054 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
VS-5584 1246560-33-7 PI3K/Akt/mTOR signaling PI3K mTOR Phosphoinositide 3-kinase inhibit SB2343 SB-2343 Inhibitor SB 2343 VS 5584 VS5584 Mammalian target of Rapamycin inhibitor